In low-grade gliomas (Grades 2 and 3), TERT-p mutant patients have a better prognosis than wildtype patients, but in GBs (Grade 4), TERT-p mutations are associated with poor outcomes [25,26]. The gene discussed is TERT; the disease is central nervous system cancer.